BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 38539511)

  • 1. Immune Checkpoint Inhibitors and Male Fertility: Should Fertility Preservation Options Be Considered before Treatment?
    Ntemou E; Delgouffe E; Goossens E
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.
    Ando H; Suzuki K; Yanagihara T
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors and Associated Pituitary Dysfunctions: A Mini-Review.
    Fukuda I
    J Nippon Med Sch; 2023 May; 90(2):149-156. PubMed ID: 36823122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
    Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL
    Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive review about the utilization of immune checkpoint inhibitors and combination therapy in hepatocellular carcinoma: an updated review.
    Sharafi F; Hasani SA; Alesaeidi S; Kahrizi MS; Adili A; Ghoreishizadeh S; Shomali N; Tamjidifar R; Aslaminabad R; Akbari M
    Cancer Cell Int; 2022 Aug; 22(1):269. PubMed ID: 35999569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cutaneous Adverse Events Associated with Immune Checkpoint Inhibitors: A Review Article.
    Chen CH; Yu HS; Yu S
    Curr Oncol; 2022 Apr; 29(4):2871-2886. PubMed ID: 35448208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biomarkers for Immune Checkpoint Inhibitor-Mediated Tumor Response and Adverse Events.
    Nakamura Y
    Front Med (Lausanne); 2019; 6():119. PubMed ID: 31192215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer.
    Wang F; Xia T; Li Z; Gao X; Fang X
    Front Oncol; 2023; 13():1213297. PubMed ID: 37727216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ileus in patients treated with immune checkpoint inhibitors: A retrospective, pharmacovigilance study using Food and Drug Administration Adverse Event Reporting System database.
    Gao S; He Z; Zhu J; Liang D; Zhao W; Yang S; Jiang W; Qiu K; Yu X; Wu J
    Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1199-1205. PubMed ID: 35689298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors.
    Chennamadhavuni A; Abushahin L; Jin N; Presley CJ; Manne A
    Front Immunol; 2022; 13():779691. PubMed ID: 35558065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
    Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
    Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune-related adverse events in various organs caused by immune checkpoint inhibitors.
    Okiyama N; Tanaka R
    Allergol Int; 2022 Apr; 71(2):169-178. PubMed ID: 35101349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review.
    Naltet C; Besse B
    Transl Lung Cancer Res; 2021 Jun; 10(6):3014-3028. PubMed ID: 34295694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.
    Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W
    Front Immunol; 2023; 14():1175809. PubMed ID: 37520574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors.
    Das S; Johnson DB
    J Immunother Cancer; 2019 Nov; 7(1):306. PubMed ID: 31730012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
    Vaddi A; Hulsebus HJ; O'Neill EL; Knight V; Chan ED
    J Thorac Dis; 2024 Feb; 16(2):1601-1624. PubMed ID: 38505086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.